Lancashire & South Cumbria Cancer Network

Systemic Anticancer Treatment Protocol

Drug regimen
3-Weekly Carboplatin/weekly paclitaxel

Indications for use
Ovarian cancer, endometrial adenocarcinoma, carcinoma of cervix, NSCLC, early breast cancer (neoadjuvant)

Regimen
Week 1
Pre-medicate 30 mins pre chemo with:

Chlorphenamine 10mg	I.V. bolus
Ranitidine 50mg	50mls 0.9% NaCl
Dexamethasone 10mg	100mls 0.9% NaCl

For subsequent weeks reduce dexamethasone dose to 8mg. If patient experiences any hypersensitivity reaction do not reduce the dose further but continue on the same or increased dose of dexamethasone. If severe reaction, change regimen/ remove offending agent:

DRUG	FLUID	TIME	ROUTE
Paclitaxel 80mg/m²	250mls 0.9% sodium chloride	1 hour	I.V
Carboplatin AUC 6	500mls 5% Glucose	1 hour	I.V
Maximum carboplatin dose=890mg			

Week 2:

Paclitaxel 80mg/m²	250mls 0.9% sodium chloride	1 hour	I.V

Week 3:

Paclitaxel 80mg/m²	250mls 0.9% sodium chloride	1 hour	I.V

Regimen to be given every 3 weeks for 6 cycles (4 cycles for neoadjuvant breast cancer followed by EC or AC chemotherapy)

Investigation prior to initiating treatment
FBC, U&Es, LFTs, Calcium, random glucose

Cautions
In the event of severe neuropathy or severe hypersensitivity reactions it may be necessary to discontinue paclitaxel (or carboplatin if allergy is to carboplatin)

Investigations and consultations prior to each cycle
FBC U&Es and LFTs
Magnesium once a month, random glucose or BM once a month
Consultation every three weeks The U&Es and LFTs) need to be checked the day before so that results are available pre-chemotherapy

Acceptable levels for treatment proceed before **day 1**
(If outside these levels delay one week or contact consultant)
Delay treatment 1 week or until platelets ≥100 and neutrophils ≥1.5
If Neutrophils 1.2 – 1.5 contact **consultant**

Acceptable levels for treatment proceed before **days 8 & 15** are administered
(If outside these levels delay one week or contact consultant)
Delay treatment 1 week or until platelets ≥75 and neutrophils ≥0.8

Side effects
Hypersensitivity reactions, myalgia, neuropathy, alopecia, nausea and vomiting, fatigue, bone marrow suppression, rash

Dose Modification Criteria

	Starting dose	**Dose level -1**	**Dose level -2**
Carboplatin	AUC6	AUC5	AUC4
Paclitaxel	80mg/m^2	60-80mg/m^2	45-60mg/m^2

Reduce dose by 1 dose level in the event of multiple delays due to haematological toxicity
Withhold paclitaxel in the event of grade ≥2 neuropathy until resolved to grade ≤1 and restart at reduced dose level
Discontinue paclitaxel if transaminases >5 x ULN

Specific Information on Administration

Important – Use non PVC IV giving set with paclitaxel.
Paclitaxel must be given before carboplatin

THIS PROTOCOL HAS BEEN DIRECTED BY DR YIANNAKIS, CONSULTANT ONCOLOGIST

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

DATE **March 2019**
REVIEW **March 2021**
VERSION **9**